DAPA-HF trial signals the birth of ‘diabetic cardiology’ and more

Authors

  • Kerolos Wagdy Adult cardiology department, Aswan Heart Centre, Aswan, Egypt
  • Peter Selwanos Adult cardiology department, Aswan Heart Centre, Aswan, Egypt

DOI:

https://doi.org/10.21542/gcsp.2020.22

Abstract

[no abstract - showing first paragraph of article]

Sodium-glucose co-transporter-2 (SGLT2) inhibitors are relatively new class of antihyperglycemic medication that is well established in the management of type 2 diabetes mellitus (DM). It has a unique mechanism of action that targets the kidneys through inhibiting 90% of glucose reabsorption.

Downloads

Published

2020-12-06

Issue

Vol. 2020 No. 2 (2020)

Section

Lessons from the trials

License

This is an open access article distributed under the terms of the Creative Commons Attribution license CC BY 4.0, which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.